Friday 6 November 2026
Export ISPC’s income statement to Excel — free account
iSpecimen Inc.
ISPC Healthcare Diagnostics & Research
iSpecimen Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.9 million, down 79.2% from fiscal 2024.
- Revenue
- −78.7%
- EPS
- +94.2%
- Free cash flow
- −257.7%
Quarter to June 2026, against a year earlier
0.80
0.04
−4.76%
Follow ISPC
Alert me
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
Piotroski F-Score |
+8 more TTM periods Free account |
2 | 3 | 3 | 3 |
| (296.20%) | (327.77%) | (894.60%) | (968.44%) | ||
| (113.84%) | (111.09%) | (165.08%) | (170.09%) | ||
ROIC |
(2,615.23%) | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
561.54% | (1,400.56%) | 530.64% | 1,175.48% | |
Average Days of Receivables |
13.16 | 9.14 | 47.17 | 16.67 | |
Free Cash Flow per Share |
(55.65) | (27.43) | (24.04) | (6.24) | |
Free Cash Flow |
(8.12) | (5.31) | (8.21) | (8.70) | |
Capital Expenditures |
(1.23) | (1.07) | (1.70) | (1.70) | |
| Other line items | |||||
Cash ROIC |
(138.76%) | (53.31%) | (225.90%) | (141.51%) | |
Accounts Receivable Turnover |
2.44 | 2.58 | 2.88 | 2.37 | |
Accounts Payable Turnover |
0.60 | 0.40 | 0.31 | 0.22 | |
Inventory Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
662.06 | 1,027.53 | 1,289.94 | 1,756.03 | |
Days of Inventory on Hand |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
9.93% | 12.80% | 18.23% | 26.96% | |
Selling, General and Administrative Expense of Revenue |
265.39% | 299.00% | 670.04% | 1,429.32% | |
Share Based Compensation of Revenue |
0.91% | 1.10% | 0.62% | 1.03% | |
Interest Coverage |
(72.72) | (56.32) | — | — | |
Operating CF/Net income |
0.60 | 0.40 | 0.59 | 0.61 | |
Depreciation/Fixed assets |
43.72 | 67.88 | 62.08 | 57.28 | |
Capex/Depreciation |
(0.66) | (0.62) | (1.19) | (1.41) | |
Revenue per Share |
22.96 | 9.96 | 3.01 | 0.33 | |
Operating CF per Share |
(47.24) | (21.89) | (19.06) | (5.02) | |
Capex per Share |
(8.41) | (5.54) | (4.98) | (1.22) | |
Capex to Sales |
0.37 | 0.56 | 1.66 | 3.65 |
Columns are period end dates · fundamentals updated 26 Oct 2026